Cell cycle inhibitors represent a key approach to the treatment of cancer. Therapeutic agents have traditionally targeted early stages of the cell cycle (ie the G1/S phase checkpoint or the S phase) or mitotic spindle formation as exemplified by the alkaloids. Recently a new approach to cell cycle regulation has emerged with the identification of the Aurora kinase family. This family plays a role in later stages of the cell cycle from the G2/M check point all the way through to the mitotic checkpoint and late mitosis.
Aurora Kinase Inhibitors: The dawn of a new approach to cancer was written as a target evaluation/drug development update report. This analysis was intended to provide a framework for all organizations considering entry into this exciting field or those already in the field but who require competitive intelligence within the area. The report:
- Introduces the Aurora kinases - Analyzes the proof of concept supporting the development of aurora kinase inhibitors for the treatment of cancer - Discusses mechanism of action - Evaluates drugs in development - Provides strategic guidance on kinase selectivity - Discusses the promise and risks of kinase inhibitors - Offers competitive intelligence discussing how Aurora kinase inhibitors would fit into the current oncology treatment area.
The report compares this class with existing and emerging classes and evaluates the part that Aurora kinase inhibitors could play in the combinatorial approach to cancer
